tiprankstipranks
AstraZeneca (DE:ZEGA)
:ZEGA
Germany Market

AstraZeneca (ZEGA) Stock Forecast & Price Target

Compare
2 Followers
See the Price Targets and Ratings of:

ZEGA Analyst Ratings

Strong Buy
6Ratings
6 Buy
0 Hold
0 Sell
Based on 6 analysts giving stock ratings to
AstraZeneca
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ZEGA Stock 12 Month Forecast

Average Price Target

€84.57
▲(19.11% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is €84.57 with a high forecast of €88.94 and a low forecast of €80.69. The average price target represents a 19.11% change from the last price of €71.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"56":"€56","89":"€89","64.25":"€64.3","72.5":"€72.5","80.75":"€80.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":88.9397462,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€88.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84.566111258,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€84.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80.6876048,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€80.69</span>\n  </div></div>","useHTML":true}}],"tickPositions":[56,64.25,72.5,80.75,89],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Sep<br/>2024","9":"Dec<br/>2024","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72,73.3030574,74.6061148,75.9091722,77.2122296,78.515287,79.8183444,81.1214018,82.4244592,83.7275166,85.030574,86.3336314,87.6366888,{"y":88.9397462,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72,72.96662394292308,73.93324788584616,74.89987182876924,75.86649577169231,76.83311971461539,77.79974365753847,78.76636760046154,79.73299154338461,80.69961548630769,81.66623942923077,82.63286337215385,83.59948731507693,{"y":84.566111258,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72,72.66827729230769,73.33655458461539,74.00483187692308,74.67310916923077,75.34138646153846,76.00966375384616,76.67794104615385,77.34621833846154,78.01449563076923,78.68277292307693,79.35105021538462,80.01932750769231,{"y":80.6876048,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":57.324,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.244,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.573,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.083,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.063,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.493,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.395,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.521,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.592,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.592,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.113,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€88.94Average Price Target€84.57Lowest Price Target€80.69
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Erste Group
Hold
Downgraded
09/30/24
AstraZeneca downgraded to Hold from Buy at Erste GroupAstraZeneca downgraded to Hold from Buy at Erste Group
BOCOM International Holdings Company Analyst forecast on DE:ZEGA
Unknown Analyst
Not Ranked
BOCOM International Holdings Company
€85.55
Buy
20.49%
Upside
Initiated
07/18/24
BOCOM Intl starts AstraZeneca (AZN) at BuyBOCOM Intl initiates coverage on AstraZeneca (NASDAQ: AZN) with a Buy rating and a price target of $93.30.
Jefferies
€67.85
Hold
-4.44%
Downside
Reiterated
07/02/24
AstraZeneca (AZN) Gets a Hold from Jefferies
Argus Research
€73.35€77.94
Buy
9.77%
Upside
Reiterated
05/30/24
AstraZeneca price target raised to $85 from $80 at ArgusAstraZeneca price target raised to $85 from $80 at Argus
Morgan Stanley
€77.94€77.02
Buy
8.48%
Upside
Reiterated
04/22/24
AstraZeneca (AZN) PT Lowered to $84 at Morgan StanleyMorgan Stanley analyst Mark Purcell lowered the price target on AstraZeneca (NASDAQ: AZN) to $84.00 (from $85.00) while maintaining a Overweight rating.
Oddo BHF
Hold
Downgraded
03/13/24
AstraZeneca downgraded to Neutral from Outperform at Oddo BHFAstraZeneca downgraded to Neutral from Outperform at Oddo BHF
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Erste Group
Hold
Downgraded
09/30/24
AstraZeneca downgraded to Hold from Buy at Erste GroupAstraZeneca downgraded to Hold from Buy at Erste Group
BOCOM International Holdings Company Analyst forecast on DE:ZEGA
Unknown Analyst
Not Ranked
BOCOM International Holdings Company
€85.55
Buy
20.49%
Upside
Initiated
07/18/24
BOCOM Intl starts AstraZeneca (AZN) at BuyBOCOM Intl initiates coverage on AstraZeneca (NASDAQ: AZN) with a Buy rating and a price target of $93.30.
Jefferies
€67.85
Hold
-4.44%
Downside
Reiterated
07/02/24
AstraZeneca (AZN) Gets a Hold from Jefferies
Argus Research
€73.35€77.94
Buy
9.77%
Upside
Reiterated
05/30/24
AstraZeneca price target raised to $85 from $80 at ArgusAstraZeneca price target raised to $85 from $80 at Argus
Morgan Stanley
€77.94€77.02
Buy
8.48%
Upside
Reiterated
04/22/24
AstraZeneca (AZN) PT Lowered to $84 at Morgan StanleyMorgan Stanley analyst Mark Purcell lowered the price target on AstraZeneca (NASDAQ: AZN) to $84.00 (from $85.00) while maintaining a Overweight rating.
Oddo BHF
Hold
Downgraded
03/13/24
AstraZeneca downgraded to Neutral from Outperform at Oddo BHFAstraZeneca downgraded to Neutral from Outperform at Oddo BHF
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

Which Analyst Should I Follow If I Want to Buy DE:ZEGA and Sell After:
1 Month
xxx
Success Rate
23/34 ratings generated profit
68%
Average Return
+2.66%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 67.65% of your transactions generating a profit, with an average return of +2.66% per trade.
3 Months
xxx
Success Rate
14/21 ratings generated profit
67%
Average Return
+4.98%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +4.98% per trade.
1 Year
Steve ScalaTD Cowen
Success Rate
18/21 ratings generated profit
86%
Average Return
+12.85%
reiterated a buy rating last month
Copying Steve Scala's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +12.85% per trade.
2 Years
xxx
Success Rate
30/34 ratings generated profit
88%
Average Return
+16.24%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 88.24% of your transactions generating a profit, with an average return of +16.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZEGA Analyst Recommendation Trends

Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
0
0
0
0
0
Buy
16
13
17
15
14
Hold
1
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
13
17
15
15
In the current month, ZEGA has received 14 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ZEGA average Analyst price target in the past 3 months is €84.57.
Each month's total comprises the sum of three months' worth of ratings.

ZEGA Financial Forecast

ZEGA Earnings Forecast

Next quarter’s earnings estimate for ZEGA is €1.02 with a range of €0.98 to €1.08. The previous quarter’s EPS was €0.96. ZEGA beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 66.67% of the time in the same period. In the last calendar year ZEGA has Outperformed its overall industry.
Next quarter’s earnings estimate for ZEGA is €1.02 with a range of €0.98 to €1.08. The previous quarter’s EPS was €0.96. ZEGA beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 66.67% of the time in the same period. In the last calendar year ZEGA has Outperformed its overall industry.

ZEGA Sales Forecast

Next quarter’s sales forecast for ZEGA is €12.66B with a range of €12.44B to €12.88B. The previous quarter’s sales results were €13.71B. ZEGA beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 64.71% of the time in the same period. In the last calendar year ZEGA has Outperformed its overall industry.
Next quarter’s sales forecast for ZEGA is €12.66B with a range of €12.44B to €12.88B. The previous quarter’s sales results were €13.71B. ZEGA beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 64.71% of the time in the same period. In the last calendar year ZEGA has Outperformed its overall industry.

ZEGA Stock Forecast FAQ

What is DE:ZEGA’s average 12-month price target, according to analysts?
Based on analyst ratings, AstraZeneca’s 12-month average price target is €84.57.
    What is DE:ZEGA’s upside potential, based on the analysts’ average price target?
    AstraZeneca has 19.11% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AstraZeneca a Buy, Sell or Hold?
          AstraZeneca has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
            What is AstraZeneca’s share price target?
            The average share price target for AstraZeneca is €84.57. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €88.94 ,and the lowest forecast is €80.69. The average share price target represents 19.11% Increase from the current price of €71.
              What do analysts say about AstraZeneca?
              AstraZeneca’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of AstraZeneca?
                To buy shares of DE:ZEGA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis